Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

BACKGROUND: The COVID-19 vaccine candidate CVnCoV comprises sequence-optimized mRNA encoding SARS-CoV-2 S-protein encapsulated in lipid nanoparticles. In this phase 2a study, we assessed reactogenicity and immunogenicity of two or three doses in younger and older adults. METHODS: Younger (18–60 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Sáez-Llorens, Xavier, Lanata, Claudio, Aranguren, Elaine, Celis, Carlos R., Cornejo, Rubelio, DeAntonio, Rodrigo, Ecker, Lucie, Garrido, Diegi, Gil, Ana I., Gonzales, Marina, Hess-Holtz, Morgan, Leroux-Roels, Geert, Junker, Helga, Kays, Sarah-Katharina, Koch, Sven D., Lazzaro, Sandra, Mann, Philipp, Quintini, Gianluca, Srivastava, Barkha, Vahrenhorst, Dominik, von Eisenhart-Rothe, Philipp, Wolz, Olaf-Oliver, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247226/
https://www.ncbi.nlm.nih.gov/pubmed/35791320
http://dx.doi.org/10.1016/j.jvacx.2022.100189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247226/
https://www.ncbi.nlm.nih.gov/pubmed/35791320
http://dx.doi.org/10.1016/j.jvacx.2022.100189

Ejemplares similares